Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting
Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting
This single arm, post-authorisation study is designed to evaluate the long-term safety of pirfenidone in participants with IPF. The enrolment of participants will be completed within approximately 24 months. Participants will receive pirfenidone according to the physician discretion and will be followed for 2 years. Treating physicians will collect pre-specified data at the baseline and every 3 months thereafter, for the duration of the participants' participation in study.
Inclusion Criteria:
Exclusion Criteria:
Innsbruck, 6020, Austria
Berlin, 13353, Germany
Berlin, 14089, Germany
Berlin, 14165, Germany
Coswig, 01640, Germany
Esslingen am Neckar, 73730, Germany
Frankfurt am Main, 60596, Germany
Giessen, 35392, Germany
Greifswald, 17489, Germany
Großhansdorf, 22927, Germany
Homburg/Saar, 66421, Germany
Leipzig, 04103, Germany
Magdeburg, 39120, Germany
München, 81377, Germany
Nuremberg, 90419, Germany
Treuenbrietzen, 14929, Germany
Modena, Emilia-Romagna 41124, Italy
Monza, Lombardy 20052, Italy
Orbassano (TO), Piedmont 10043, Italy
Siena, Tuscany 53100, Italy
Stokholm, Solna, 17176, Sweden
Hampshire, SO16 6YD, United Kingdom
Liecester, L9 7AL, United Kingdom